Monthly Archives: May 2016

The Drop in OPDP Enforcement

Back when the Office of Prescription Drug Promotion (OPDP) issued regulatory action letters on a regular basis (either Warning Letters or Untitled Letters) regarding what the agency saw as infractions in the course of promotional speech, I would post a … Continue reading

Posted in Warning Letters | Comments Off on The Drop in OPDP Enforcement

More Space on Twitter – Does it Change Things for Pharma?

This week media carried reports that Twitter was going to making a shift in policy regarding space. Until now, you have been limited to 140 characters in your tweeting which included space for your – albeit tiny – URL and/or … Continue reading

Posted in Social Media | Comments Off on More Space on Twitter – Does it Change Things for Pharma?

Which Way on the Public Health Narrative on Zika?

Back in February in a post entitled “From HIV to Zika – The Role of Communications“, I listed several of the hallmark characteristics involving the communications environment and emerging pathogens, drawing not only on recent observations with respect to Ebola, … Continue reading

Posted in Current Affairs | Tagged , | Comments Off on Which Way on the Public Health Narrative on Zika?